<DOC>
	<DOCNO>NCT00227110</DOCNO>
	<brief_summary>To determine role pioglitazone treatment nonalcoholic steatohepatitis ( NASH ) patient glucose intolerance type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>Role Pioglitazone Treatment Non-alcoholic Steatohepatitis ( NASH )</brief_title>
	<detailed_description>v. 4/1/2003 Role Pioglitazone Treatment Nonalcoholic Steatohepatitis 1 . PURPOSE/SPECIFIC AIMS To determine role pioglitazone treatment nonalcoholic steatohepatitis ( NASH ) patient glucose intolerance type 2 diabetes mellitus ( T2DM ) . NASH disease characterize elevated plasma aminotransferases histopathological change liver characterize hepatocellular steatosis , chronic inflammation fibrosis ( 1-3 ) . Pioglitazone , new thiazolidinedione ( TZD ) , proven safe effective treatment type 2 diabetes mellitus ( T2DM ) ( 4 ) . NASH affect ~10-20 % obese type 2 diabetic subject ( 1-3 , 5 , 6 ) . While pathogenesis NASH poorly understand , consensus insulin resistance associate abnormality lipid metabolism play key role development liver fat accumulation , TNF-alpha major mediator progression liver damage ( 7-9 ) . Currently , satisfactory therapy NASH . Pioglitazone improve insulin sensitivity glycemic control patient T2DM ( 4 , 10-12 ) , mechanism action TZDs unclear ( 13 , 14 ) . Pioglitazone activate gene involve lipid synthesis , cause reduction plasma free fatty acid ( FFA ) triglyceride ( 15 ) . TZDs decrease excessive triglyceride accumulation liver ( 16 ) , muscle ( 17 ) , visceral fat ( 11 , 16 , 18 ) , redistribution fat subcutaneous adipose store ( 14 ) . TZDs also antagonize metabolic effect TNF-alpha ( 19-22 ) . Because pioglitazone ameliorates insulin resistance , reverse metabolic abnormality contribute hepatic fat infiltration ( increase plasma glucose , FFA , triglyceride concentration ) , antagonizes effect TNF-alpha , follow pioglitazone may prove useful treatment patient NASH . In order evaluate hypothesis , plan treat 6 month group patient impair glucose tolerance ( IGT ) T2DM pioglitazone randomize , double-blinded , placebo-controlled trial . Three major endpoint measure treatment ( see Methods detailed description ) : 1 . Liver histologic response ; assess liver biopsy . Steatosis inflammatory change quantify use standardize staging system . 2 . Liver fat content : measure liver magnetic resonance spectroscopy ( MRS ) . 3 . Hepatic insulin sensitivity glucose metabolism : Because fat infiltration liver muscle cause insulin resistance impairs glucose tolerance , measure parameter metabolic control include fast plasma glucose , free fatty acid , fructosamine , HbA1c fast lipid profile . To assess effect pioglitazone hepatic insulin sensitivity , fast ( basal ) postprandial hepatic glucose production study use double-tracer technique ( infusion 3-3H glucose combine oral glucose load radiolabeled 1-14C glucose ) ( 23 ) . Glucose lipid oxidation measure indirect calorimetry ( 24 ) . In addition , index hepatic peripheral insulin sensitivity derive oral glucose tolerance test ( OGTT ) ( 25 ) .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>1 . Be able communicate meaningfully Investigator legally competent provide write informed consent . 2 . Patients must age range 21 70 year ( inclusive ) . 3 . NASH confirm liver biopsy . 4 . Subjects must meet criterion impair glucose tolerance ( FPG concentration &lt; 126 mg/dl two hour plasma glucose value oral glucose tolerance test [ OGTT ] ≥140 &lt; 200 mg/dl ) type 2 diabetes mellitus ( FPG concentration ≥ 126 mg/dl two hour plasma glucose value OGTT ≥200 mg/dl ) ( 62 ) . Subjects FPG great 260 mg/dl exclude study . 5 . Diabetic patient allow sulfonylureas repaglinide metformin , thiazolidinedione insulin . Patients must stable dose allow chronic medication four week prior enter doubleblind treatment period . 6 . Female patient must nonlactating must either least two year postmenopausal , use adequate mechanical contraceptive precaution ( i.e . intrauterine device , diaphragm spermicide , condom spermicide ) , surgically sterilize ( i.e . bilateral tubal ligation , bilateral oophorectomy ) . Female patient undergone hysterectomy eligible participation study . Female patient ( except patient undergone hysterectomy bilateral oophorectomy ) eligible negative pregnancy test throughout study period . Patients oral contraceptive hormonal implant exclude . 7 . All participant must follow laboratory value : Hemoglobin ≥ 13 gm/dl male , ≥ 12 gm/dl female WBC count ≥ 3,000/mm3 Neutrophil count ≥ 1,500/mm3 Platelets ≥ 100,000/mm3 Prothrombin time within 3 second control Albumin ≥3.0 g/dl Serum creatinine ≤ 1.6 mg/dl Creatinine phosphokinase ≤ 2 time upper limit normal AST ( SGOT ) ≤ 2.5 time upper limit normal ALT ( SGPT ) ≤ 2.5 time upper limit normal Alkaline phosphatase ≤ 2.5 time upper limit normal 1 . Any cause chronic liver disease NASH ( restrict alcohol drug abuse , medication , chronic hepatitis B C , autoimmune , hemochromatosis , Wilson 's disease , alpha1antitrypsin deficiency ) . 2 . Any clinical evidence history ascitis , bleed varix , spontaneous encephalopathy . 3 . No past ( least 1 year ) current history alcohol abuse ( alcohol consumption great one drink per day ) . 4 . Prior surgical procedure include gastroplasty , jejunoileal jejunocolic bypass . 5 . Prior exposure organic solvent carbon tetrachloride . 6 . Total parenteral nutrition ( TPN ) within past 6 month . 7 . Diabetics FPG great 260 mg/dl initial visit . 8 . Diabetics take metformin , thiazolidinedione insulin . 9 . Subjects type 1 diabetes mellitus . 10 . Patients chronic medication know adverse effect glucose tolerance level unless patient stable dose agent 4 week entry study . Patients estrogens hormonal replacement therapy , tamoxifen , raloxifene , oral glucocorticoid chloroquine exclude . 11 . Patients history clinically significant heart disease ( New York Heart Classification great grade II ; nonspecific STT wave change EKG ) , peripheral vascular disease ( history claudication ) , pulmonary disease ( dyspnea exertion one flight le ; abnormal breath sound auscultation ) , study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>NASH , IGT , T2DM</keyword>
</DOC>